Pharmacokinetic Optimization of Immune Checkpoint Inhibitors in Oncology

Pharmacokinetic optimisation of immune checkpoint inhibitors (ICIs) seeks to fine-tune dosing and scheduling to maximise antitumour efficacy while minimising toxicity and cost. By characterising absorption, distribution, metabolism and excretion of monoclonal antibodies such as pembrolizumab, nivolumab and atezolizumab, researchers have moved beyond one-size-fits-all regimens towards model-informed and patient-adapted approaches. Population pharmacokinetic (PopPK) models integrate diverse covariates—body weight, serum albumin, gender and disease state—to predict interindividual variability in clearance and volume of distribution. These models underpin the transition from weight-based to fixed dosing and support alternative schedules that maintain plasma concentrations above receptor-saturation thresholds. Exposure–response and exposure–safety analyses have defined target concentration ranges associated with maximal clinical benefit, guiding choices of flat versus tailored dosing. Concurrently, real-world and post-marketing studies have evaluated immunogenicity and economic impact, reinforcing flexible regimens that preserve therapeutic index and expand global access. Concrete examples include flat-dose pembrolizumab at 200 mg every three weeks and extended-interval atezolizumab regimens validated by simulation and clinical data. Collectively, these advances illustrate a data-driven evolution in ICI use, balancing precision medicine with practical considerations in oncology practice.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacokinetic Optimization of Immune Checkpoint Inhibitors in Oncology publication trend

The graph below shows the total number of articles in pharmacokinetic optimization of immune checkpoint inhibitors in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacokinetics: Study of how a drug is absorbed, distributed, metabolised and excreted over time.

Population pharmacokinetics: Analysis of drug concentration data to characterise variability across individuals and identify influencing covariates.

Exposure–response relationship: Correlation between drug concentration and the magnitude of therapeutic or adverse effects.

Clearance: Volume of plasma from which a drug is completely removed per unit time, reflecting elimination efficiency.

Area under the concentration–time curve (AUC): Integral of plasma concentration over time, representing total drug exposure.

Immunogenicity: Ability of a therapeutic protein to provoke an immune response that may alter pharmacokinetics or efficacy.

References

1. Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for ImmunoTherapy of Cancer (2017).
2. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology (2019).
3. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. Journal for ImmunoTherapy of Cancer (2019).
4. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Medicine (2020).